Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Society for the Study of Lung Cancer/Association of Molecular Pathologists Guideline

This is a clinical practice guideline endorsement for the selection of patients with lung cancer for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors. The guideline addresses five principal questions including considerations about when molecular testing should be performed, the manner in which EGFR testing should be performed, and whether other genes should be routinely tested in lung adenocarcinoma. Other areas of interest include recommendations as to how EGFR and ALK testing should be validated, and how best to maintain quality control and quality assurance policies and procedures for EGFR and ALK testing in lung cancers.